Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292223 · ClinicalTrials.gov registry record · Phase 4
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
A Phase 4 study of Parkinson Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 18
- Study locations
NCT04292223: Completed Phase 4 study of Parkinson Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
NCT04292223 is a Phase 4 study of Parkinson Disease Psychosis that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 29 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04292223, a Phase 4 study of Parkinson Disease Psychosis, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 18
- Study locations
Study Summary
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
Primary Outcome
The mFSQ is a self-administered questionnaire. It comprises 34 core items that produce 6 summary scale scores (i.e. basic activities of daily living (ADL); intermediate ADL; psychological function and mental health; work performance, social activity, and quality of interaction) and 6 single-item scores (work situation; days/month in bed due to illness/injury; days/month when illness/injury reduced activities normally performed for half a day; satisfaction with sexual relationship; satisfaction w
Conditions Studied
Interventions
- DRUG Pimavanserin
Study Locations (18)
Florida
- Premier Clinical Research Institute, Inc. - Miami
- Global Health Research Center, Inc. - Miami Lakes
- Quantum Laboratories, Inc. - Pompano Beach
- Parkinson's Disease Treatment Center of Southwest Florida - Port Charlotte
- Accel Research Sites - Brain and Spine Institute - Port Orange
- Infinity Clinical Research, LLC - Sunrise
- Premiere Research Institute at Palm Beach Neurology - West Palm Beach
Ohio
- Neurology Diagnostics, Inc. - Dayton
- The Orthopedic Foundation - New Albany
Arizona
- Movement Disorders Center of Arizona - Scottsdale
California
- Neurology Center of North Orange County - Fullerton
Georgia
- AU Movement and Memory Disorders - Augusta
Maine
- Maine Medical Partners Neurology - Scarborough
New Hampshire
- Wentworth Health Partners Coastal Neurology Services - Dover
New Jersey
- Bio Behavioral Health - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 4 |
What the finished NCT04292223 record still lists
NCT04292223 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Parkinson Disease Psychosis appearing as the primary indexed condition, and to 1 intervention - of which Pimavanserin is the first listed.
NCT04292223 lists 18 locations in 11 states (Florida, Ohio, Arizona).
Frequently Asked Questions
What is clinical trial NCT04292223 about?
NCT04292223 is a clinical study titled "Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis". To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
What is the current status of trial NCT04292223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2020-02-10. Estimated completion is 2022-04-26.
What conditions does trial NCT04292223 study?
This clinical trial studies the following conditions: Parkinson Disease Psychosis.
What interventions are being tested in trial NCT04292223?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT04292223?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04292223 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Georgia, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04292223's enrollment target sits among peer trials
29 1634th of 2000 higher than 366 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI